STOCK TITAN

[SC 13E3/A] Enstar Group Amended Going Private Transaction

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC 13E3/A
Rhea-AI Filing Summary

Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.

  • Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
  • Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
  • Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.

Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle prestazioni del 16 marzo 2023. Per coprire le tasse di ritenuta, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo la vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un aumento di circa 132 mila azioni rispetto al saldo precedente.

  • Natura della transazione: il codice “A” indica un'acquisizione da premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una transazione sul mercato aperto.
  • Base di costo: le RSU sono state assegnate senza costi in contanti per l'insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull'allineamento: l'esecutivo mantiene una significativa partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l'allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In generale, la segnalazione riflette una vesting ordinaria di compensi azionari e la relativa ritenuta fiscale piuttosto che una decisione discrezionale di acquisto o vendita. L'impatto sul mercato è previsto neutro in assenza di altri fattori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, listado como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso recibió 217,523 acciones Clase A a través del tramo final de una adjudicación de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a $2.79 por acción. Tras la venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento aproximado de 132 mil acciones respecto al saldo previo.

  • Naturaleza de la transacción: El código “A” indica adquisición por premio de acciones; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en el mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación accionaria considerable (≈3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó una inversión de efectivo nueva.

En general, la presentación refleja una consolidación rutinaria de compensación en acciones y la retención fiscal correspondiente, más que una decisión discrecional de compra o venta. Se espera que el impacto en el mercado sea neutral salvo otros factores.

Form 4 제출 개요: Clover Health Investments (CLOV)는 “CEO, Medicare Advantage”로 등재된 Jamie L. Reynoso의 내부자 활동을 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 수여의 마지막 분할로 217,523 클래스 A 주식을 취득했습니다. 원천징수세를 충당하기 위해 회사는 자동으로 85,596주를 주당 $2.79에 판매했습니다. 자동 판매 후 Reynoso 씨의 직접 소유 주식은 3,328,328 클래스 A 주식으로, 이전 잔액 대비 약 13.2만 주 증가했습니다.

  • 거래 성격: “A” 코드는 지분 수여에 의한 취득을, “F” 코드는 세금 원천징수를 위한 주식 보유를 나타내며, 둘 다 공개 시장 거래를 의미하지 않습니다.
  • 원가 기준: RSU는 내부자에게 현금 비용 없이 정산되었으며, 세금 원천징수 판매만 시장 가격이 적용됩니다.
  • 정렬 영향: 임원은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화하지만, 새로운 현금 투자는 이루어지지 않았습니다.

전반적으로 이번 제출은 임의의 매매 결정이 아닌 정기적인 주식 보상 베스팅 및 관련 세금 원천징수를 반영합니다. 다른 촉매가 없다면 시장 영향은 중립적일 것으로 예상됩니다.

Vue d'ensemble du dépôt du formulaire 4 : Clover Health Investments (CLOV) a rapporté une activité d'initié de Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a reçu 217 523 actions de classe A via la dernière tranche d'une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les impôts à la source, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s'élève à 3 328 328 actions de classe A, soit environ 132 000 actions de plus que le solde précédent.

  • Nature de la transaction : Le code « A » indique une acquisition via attribution d'actions ; le code « F » désigne des actions retenues pour impôts — aucune des deux n'est une transaction sur le marché libre.
  • Base de coût : Les RSU ont été attribuées sans coût en espèces pour l'initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l'alignement : La dirigeante conserve une participation importante (≈3,3 millions d'actions), renforçant l'alignement des incitations, mais aucun nouvel investissement en espèces n'a été réalisé.

Dans l'ensemble, le dépôt reflète une acquisition régulière de rémunération en actions et la retenue fiscale associée, plutôt qu'une décision discrétionnaire d'achat ou de vente. L'impact sur le marché est attendu neutre en l'absence d'autres catalyseurs.

Übersicht zur Form 4 Meldung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien aus der letzten Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Deckung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was etwa 132.000 Aktien mehr als zuvor sind.

  • Art der Transaktion: Der Code „A“ steht für den Erwerb durch Aktienzuteilung; der Code „F“ für einbehaltene Aktien zur Steuerzahlung—beides keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Baraufwand für den Insider abgewickelt; nur der steuerbedingte Verkauf hat einen Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft behält eine bedeutende Aktienbeteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Bareinlage getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Aktienvergütung und die damit verbundene Steuerabführung wider, keine diskretionäre Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser vorliegen.

Positive
  • Executive ownership rises by ~132,000 shares, increasing alignment with shareholders.
  • Performance-based vesting suggests the company met or exceeded predefined targets tied to the 2023 RSU grant.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting—neutral impact; insider’s stake increases, no open-market buying.

The 217.5 k share addition arises from a scheduled performance-based RSU vesting. The automatic 85.6 k-share sale merely covers payroll taxes. Net beneficial ownership growth of ~132 k shares (≈4 % of her prior holdings) is not large enough to signal a strong incremental vote of confidence, but it modestly enhances alignment. Because there is no discretionary purchase or sale, I view the filing as informational, not directional. Trading volume impact should be minimal.

TL;DR: Performance-based vesting confirms compensation plan progression; governance concerns minimal.

The disclosure shows Clover Health’s incentive structure functioning as designed: shares vest only after performance hurdles, with automatic tax withholding to avoid insider liquidity strain. The executive’s continued sizable ownership (3.3 M shares) exceeds common ownership guidelines, fostering shareholder alignment. There are no indications of problematic timing, 10b5-1 usage, or unusual dispositions. Therefore, the governance signal is neutral-to-slightly-positive, but not materially impactful to valuation.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle prestazioni del 16 marzo 2023. Per coprire le tasse di ritenuta, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo la vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un aumento di circa 132 mila azioni rispetto al saldo precedente.

  • Natura della transazione: il codice “A” indica un'acquisizione da premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una transazione sul mercato aperto.
  • Base di costo: le RSU sono state assegnate senza costi in contanti per l'insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull'allineamento: l'esecutivo mantiene una significativa partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l'allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In generale, la segnalazione riflette una vesting ordinaria di compensi azionari e la relativa ritenuta fiscale piuttosto che una decisione discrezionale di acquisto o vendita. L'impatto sul mercato è previsto neutro in assenza di altri fattori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, listado como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso recibió 217,523 acciones Clase A a través del tramo final de una adjudicación de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a $2.79 por acción. Tras la venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento aproximado de 132 mil acciones respecto al saldo previo.

  • Naturaleza de la transacción: El código “A” indica adquisición por premio de acciones; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en el mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación accionaria considerable (≈3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó una inversión de efectivo nueva.

En general, la presentación refleja una consolidación rutinaria de compensación en acciones y la retención fiscal correspondiente, más que una decisión discrecional de compra o venta. Se espera que el impacto en el mercado sea neutral salvo otros factores.

Form 4 제출 개요: Clover Health Investments (CLOV)는 “CEO, Medicare Advantage”로 등재된 Jamie L. Reynoso의 내부자 활동을 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 수여의 마지막 분할로 217,523 클래스 A 주식을 취득했습니다. 원천징수세를 충당하기 위해 회사는 자동으로 85,596주를 주당 $2.79에 판매했습니다. 자동 판매 후 Reynoso 씨의 직접 소유 주식은 3,328,328 클래스 A 주식으로, 이전 잔액 대비 약 13.2만 주 증가했습니다.

  • 거래 성격: “A” 코드는 지분 수여에 의한 취득을, “F” 코드는 세금 원천징수를 위한 주식 보유를 나타내며, 둘 다 공개 시장 거래를 의미하지 않습니다.
  • 원가 기준: RSU는 내부자에게 현금 비용 없이 정산되었으며, 세금 원천징수 판매만 시장 가격이 적용됩니다.
  • 정렬 영향: 임원은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화하지만, 새로운 현금 투자는 이루어지지 않았습니다.

전반적으로 이번 제출은 임의의 매매 결정이 아닌 정기적인 주식 보상 베스팅 및 관련 세금 원천징수를 반영합니다. 다른 촉매가 없다면 시장 영향은 중립적일 것으로 예상됩니다.

Vue d'ensemble du dépôt du formulaire 4 : Clover Health Investments (CLOV) a rapporté une activité d'initié de Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a reçu 217 523 actions de classe A via la dernière tranche d'une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les impôts à la source, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s'élève à 3 328 328 actions de classe A, soit environ 132 000 actions de plus que le solde précédent.

  • Nature de la transaction : Le code « A » indique une acquisition via attribution d'actions ; le code « F » désigne des actions retenues pour impôts — aucune des deux n'est une transaction sur le marché libre.
  • Base de coût : Les RSU ont été attribuées sans coût en espèces pour l'initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l'alignement : La dirigeante conserve une participation importante (≈3,3 millions d'actions), renforçant l'alignement des incitations, mais aucun nouvel investissement en espèces n'a été réalisé.

Dans l'ensemble, le dépôt reflète une acquisition régulière de rémunération en actions et la retenue fiscale associée, plutôt qu'une décision discrétionnaire d'achat ou de vente. L'impact sur le marché est attendu neutre en l'absence d'autres catalyseurs.

Übersicht zur Form 4 Meldung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien aus der letzten Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Deckung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was etwa 132.000 Aktien mehr als zuvor sind.

  • Art der Transaktion: Der Code „A“ steht für den Erwerb durch Aktienzuteilung; der Code „F“ für einbehaltene Aktien zur Steuerzahlung—beides keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Baraufwand für den Insider abgewickelt; nur der steuerbedingte Verkauf hat einen Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft behält eine bedeutende Aktienbeteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Bareinlage getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Aktienvergütung und die damit verbundene Steuerabführung wider, keine diskretionäre Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser vorliegen.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13E-3

 

RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Amendment No. 4

 

Enstar Group Limited 

(Name of the Issuer)

 

 

 

Enstar Group Limited

Elk Evergreen Investments, LLC
Elk Cypress Investments, LLC

TSSP Sub-Fund HoldCo, LLC
Dominic F. Silvester

Elk Topco, LLC

Elk Parent Limited

Elk Bidco Limited

(Names of Persons Filing Statement)

 

Ordinary Shares, par value $1.00 per share

Depositary Shares, each representing a 1/1,000th Interest in a 7.00% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series D, par value $1.00 per share

Depositary Shares, each representing a 1/1,000th 7.00% Perpetual Non-Cumulative Preference Shares, Series E, par value $1.00 per share

(Title of Class of Securities)

 

G3075 P101 (Ordinary Shares)

G3075P119*

G30759200**

(CUSIP Number of Class of Securities)

 

 

 

Enstar Group Limited  Elk Evergreen Investments, LLC   Dominic F. Silvester
Deer Ltd. Elk Cypress Investments, LLC    
Deer Merger Sub Ltd. TSSP Sub-Fund Holdco, LLC   A.S. Cooper Building, 4th Floor
  Elk Bidco Limited   26 Reid Street
A.S. Cooper Building, 4th Floor Elk Merger Sub Limited   Hamilton HM11
26 Reid Street     Bermuda
Hamilton HM11 c/o Sixth Street Partners, LLC    
Bermuda 2100 McKinney Avenue, Suite 1500    
  Dallas, Texas 75201    

  

(Name, Address, and Telephone Numbers of Person Authorized to Receive Notices and Communications on Behalf of the Persons Filing Statement)

 

 

 

With copies to

 

Krishna Veeraraghavan     Katherine M. Krause
Benjamin M. Goodchild     Elizabeth A. Cooper
Paul, Weiss, Rifkind, Wharton & Garrison LLP     Louis H. Argentieri
1285 Avenue of the Americas     Simpson Thacher & Bartlett LLP
New York, New York 10019     425 Lexington Avenue
(212) 373-3000     New York, NY 10017
      (212) 455-2000

 

 

 

This statement is filed in connection with (check the appropriate box):

 

a.x The filing of solicitation materials or an information statement subject to Regulation 14A (§§ 240.14a-1 through 240.14b-2), Regulation 14C (§§ 240.14c-1 through 240.14c-101) or Rule 13E-3(c) (§ 240.13e-3(c)) under the Securities Exchange Act of 1934.
b.¨ The filing of a registration statement under the Securities Act of 1933.
c.¨ A tender offer.
d.¨ None of the above.

 

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies:

 

Check the following box if the filing is a final amendment reporting the results of the transaction:

 

*CUSIP number for Depositary Shares, each representing a 1/1,000th interest in a 7.00% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series D, par value $1.00 per share.
**CUSIP number for Depositary Shares, each representing a 1/1,000th interest in a 7.00% Perpetual Non-Cumulative Preference Shares, Series E, par value $1.00 per share.

 

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THIS TRANSACTION, PASSED ON THE MERITS OR THE FAIRNESS OF THE TRANSACTION OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE INFORMATION CONTAINED IN THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

 

 

 

TABLE OF CONTENTS

 

SCHEDULE 13E-3 ITEMS 3
  Item 15. Additional Information 4
  Item 16. Exhibits 5

 

2

 

 

INTRODUCTION

 

This Amendment No. 4 (this “Final Amendment”) to the Rule 13e-3 Transaction Statement on Schedule 13E-3, together with the exhibits hereto (as amended, this “Transaction Statement”), is being filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by: (i) Enstar Group Limited, an exempted company limited by shares existing under the laws of Bermuda (the “Company”) and the issuer of the ordinary shares representing ownership interests in the Company, par value $1.00 per share (the “Enstar Ordinary Shares”), the depositary shares, each representing a 1/1,000th Interest in a 7.00% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series D, par value $1.00 per share (the “Series D Preferred Shares”) and the depositary shares, each representing a 1/1,000th 7.00% Perpetual Non-Cumulative Preference Shares, Series E, par value $1.00 per share (the “Series E Preferred Shares”, together with the Series D Preferred Shares, the “Depositary Shares”), that are subject to the Rule 13E-3 transaction; (ii) Elk Evergreen Investments, LLC, a Delaware limited liability company; (iii) Elk Cypress Investments, LLC, a Delaware limited liability company; (iv) TSSP Sub-Fund HoldCo, LLC, a Delaware limited liability company; (v) Dominic F. Silvester, a natural person; (vi) Elk Topco, LLC, a limited liability company existing under the laws of Bermuda; (vii) Elk Parent Limited, an exempted company limited by shares existing under the laws of Bermuda; and (viii) Elk Bidco Limited, an exempted company limited by shares existing under the laws of Bermuda (“Parent”).

 

The Transaction Statement relates to the Agreement and Plan of Merger, dated as of July 29, 2024 (as it may be amended from time to time, the “Merger Agreement”), by and among Parent, Elk Merger Sub Limited, an exempted company limited by shares existing under the laws of Bermuda and direct wholly owned subsidiary of Parent (“Parent Merger Sub”), the Company, Deer Ltd., an exempted company limited by shares existing under the laws of Bermuda (“New Company Holdco”) and Deer Merger Sub Ltd., an exempted company limited by shares existing under the laws of Bermuda and a direct wholly owned subsidiary of New Company Holdco (“Company Merger Sub”). Pursuant to the Merger Agreement, (i) Company Merger Sub merged with and into the Company (the “First Merger”), with the Company surviving the merger as a direct wholly owned subsidiary of New Company Holdco (the “First Surviving Company”); (ii) New Company Holdco merged with and into the Company (the “Second Merger”), with the Company surviving such merger (the “Second Surviving Company”); and (iii) Parent Merger Sub merged with and into the Company (the “Third Merger” and, together with the First Merger and Second Merger, the “Mergers”), with the Company surviving such merger (the “Third Surviving Company”), so that as of immediately following such Mergers, Parent directly owns all Enstar Ordinary Shares. As a result of the Mergers, Company Merger Sub, New Company Holdco and Parent Merger Sub ceased to exist as independent entities and, therefore, are no longer Filing Persons.

 

This Final Amendment is being filed pursuant to Rule 13e-3(d)(3) under the Exchange Act to report the results of the transaction that is the subject of the Transaction Statement.

 

Except as otherwise set forth herein, the information set forth in the Transaction Statement remains unchanged and is incorporated by reference into this Final Amendment. All information set forth in this Final Amendment should be read together with the information contained in or incorporated by reference in the Transaction Statement.

 

While each of the Filing Persons acknowledges that the Mergers may be deemed to constitute a “going private” transaction for purposes of Rule 13e-3 under the Exchange Act, the filing of this Final Amendment and the Transaction Statement shall not be construed as an admission by any Filing Person, or by any affiliate of a Filing Person, that, prior to the Mergers, the Company was “controlled” by any of the Filing Persons or their respective affiliates.

 

Pursuant to General Instruction F to Schedule 13E-3, the information contained in the definitive proxy statement filed under Regulation 14A of the Exchange Act with the SEC pursuant to which the Company solicited proxies from the Company’s shareholders in connection with the Merger (as amended, the “Proxy Statement”), including all annexes thereto, is incorporated herein by reference in its entirety. Responses to each item herein are qualified in their entirety by the information contained in the Proxy Statement and the annexes thereto. The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3. Terms used but not defined in this Transaction Statement shall have the meanings given to them in the Proxy Statement.

 

3

 

 

All information concerning the Company contained in, or incorporated by reference into, this Transaction Statement was supplied by the Company. Similarly, all information concerning each other Filing Person contained in, or incorporated by reference into, this Transaction Statement was supplied by such Filing Person.

 

Item 15. Additional Information

 

(c) Other material information. Item 15(c) is hereby amended and supplemented as follows:

 

On November 6, 2024, at a special general meeting of the Company’s shareholders, the Company’s shareholders voted to approve, among other things, (1) a proposal to adopt the Merger Agreement, the Statutory Merger Agreements and the Mergers and (2) on a non-binding, advisory basis, the compensation that will or may become payable by the Company to its named executive officers in connection with the Mergers.

 

In addition, on July 2, 2025, Parent, Elk Evergreen Investments, LLC and Elk Cypress Investments, LLC entered into rollover and support agreements (“New Rollover and Support Agreements”) with each of David Ni, Nazar Alobaidat and Audrey Taranto (the “New Reinvesting Shareholders”). Under the New Rollover and Support Agreements, the New Reinvesting Shareholders agreed to contribute certain of the ordinary shares of the Second Surviving Company owned by the New Reinvesting Shareholder to an indirect parent company of Parent in exchange for equity interests in such indirect parent company of Parent, which contribution and exchange happened immediately after the Second Effective Time and prior to the Third Effective Time. The New Reinvesting Shareholders, in the aggregate, will indirectly own less than 1% of Parent through such indirect parent company following such contribution and exchange. As a result of the Mergers and the transactions contemplated by the New Rollover and Support Agreements, the Enstar Ordinary Shares held by the New Reinvesting Shareholders immediately prior to the First Merger corresponding to the ordinary shares of the Second Surviving Company that were subject to such contribution and exchange were cancelled and extinguished without any conversion thereof or consideration paid therefor.

 

On July 2, 2025, each of the First Merger, the Second Merger and the Third Merger became effective pursuant to the Certificates of Merger that were issued by the Registrar of Companies in Bermuda in connection with the First Merger, the Second Merger and the Third Merger, respectively. As a result of the Mergers and the other transactions contemplated by the Merger Agreement (collectively, the “Transactions”), Parent directly owns all Enstar Ordinary Shares.

 

As a result of the Transactions, (i) each holder of Enstar Ordinary Shares issued and outstanding immediately prior to the First Effective Time (other than (a) Enstar Ordinary Shares owned by Parent, Parent Merger Sub, the Company or their respective wholly owned subsidiaries, (b) all Reinvesting Shares, (c) all Enstar Ordinary Shares subject to the Company’s equity awards (other than Company Restricted Shares) and (d) all Ordinary Shares that were Dissenting Shares) was entitled to the right to receive a total of $338 in cash, without interest, for each Enstar Ordinary Share, and (ii) the Company’s shareholders holding each class of preferred shares of the Company (the “Enstar Preferred Shares”) received a corresponding class of preferred shares of the Company, as the Third Surviving Company, and the dividend and all other preferences and privileges, relative rights, terms and conditions of each such Enstar Preferred Shares remained unchanged. Following consummation of the Transactions, holders of the Enstar Ordinary Shares no longer directly own any shares of the Company, which is the Third Surviving Company following the Mergers, and the holders of the Enstar Preferred Shares hold preferred shares of the Company (as the Third Surviving Company following the Mergers).

 

In addition, by virtue of the Mergers, each Company Restricted Share, Company RSU Award and Company PSU Award was converted into the right to receive the consideration for such award set forth in the Merger Agreement.

 

As a result of the Transactions, the Enstar Ordinary Shares and the Depositary Shares will no longer be listed on any security exchange or quotation system, including the NASDAQ Stock Market LLC (“Nasdaq”), and the Company will cease to be a publicly traded company. On July 2, 2025, the Company notified Nasdaq that the Mergers had been completed, and Nasdaq halted trading of Enstar Ordinary Shares prior to the opening of trading on July 3, 2025. The Company requested that Nasdaq file with the SEC a notification of removal from listing and registration on Form 25 (the “Ordinary Shares Form 25”) with respect to the delisting of all Enstar Ordinary Shares from Nasdaq and the deregistration of such shares under Section 12(b) of the Exchange Act.

 

5

 

 

On July 2, 2025, the Company notified representatives of Nasdaq of its determination to voluntarily withdraw the Depositary Shares from listing on Nasdaq and registration pursuant to Section 12(b) of the Exchange Act, and its intention to file a Form 25 Notification of Delisting with the SEC (the “Depositary Shares Form 25” and together with the Ordinary Shares Form 25, the “Form 25s”) on or about July 14, 2025 relating to delisting and deregistering of the Depositary Shares.

 

Following the effectiveness of the Form 25s, the Company intends to file with the SEC a certification on Form 15 requesting the termination of registration of Enstar Ordinary Shares and the Depositary Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Sections 13 and 15(d) of the Exchange Act. Such deregistration of the Enstar Ordinary Shares and the Depositary Shares will become effective 90 days after the filing of the applicable Form 25 or such shorter period as may be determined by the SEC. The Company’s reporting obligations under the Exchange Act will be suspended immediately upon the filing of Form 15.

 

In addition, on July 2, 2025, the Company issued a press release announcing the closing of the Mergers. The press release is attached as Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed concurrently with the SEC, and is incorporated by reference herein as Exhibit (a)(5)(i) hereto.

 

6

 

 

Item 16. Exhibits

 

The following exhibits are filed herewith:

 

Exhibit
No.
  Description
(a)(2)(i)   Definitive Proxy Statement of Enstar Group Limited (the “Proxy Statement”) (included in the Schedule 14A filed on October 11, 2024 and incorporated herein by reference).
(a)(2)(ii)   Form of Proxy Card (included in the Proxy Statement and incorporated herein by reference).
(a)(2)(iii)   Letter to Shareholders (included in the Proxy Statement and incorporated herein by reference).
(a)(2)(iv)   Notice of Special Meeting of Shareholders (included in the Proxy Statement and incorporated herein by reference).
(a)(2)(v)   Current Report on Form 8-K, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(vi)   Form of Email to Regulators, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(vii)   Email to Employees, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(viii)   Email to Brokers, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(ix)   Email to Investors, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(x)   Email to Investors, dated July 29, 2024 (included in Schedule 14A filed on July 29, 2024 and incorporated herein by reference).
(a)(2)(xi)   Press Release, dated September 4, 2024 (included in Schedule 14A filed on September 4, 2024 and incorporated herein by reference).
(a)(5)(i)   Press Release, dated July 2, 2025 (included in the Company’s Current Report on Form 8-K filed on July 2, 2025 and incorporated herein by reference).
(a)(5)(ii)   Current Report on Form 8-K, dated July 2, 2025 (filed by Enstar Group Limited on July 2, 2025 and incorporated herein by reference).
(b)(i)   Equity Commitment Letter dated as of July 29, 2024, by and among Elk Bidco Limited and the persons set forth on Schedule A thereto.+
(b)(ii)   Limited Guarantee dated as of July 29, 2024, by and among Enstar Group Limited and the persons set forth on Schedule A thereto.+
(b)(iii)   Facilities Commitment Letter dated as of July 29, 2024, by and between Elk Bidco Limited and Barclays Bank PLC.+
(b)(iv)   Preferred Equity Commitment Letter dated as of July 29, 2024, by and between Elk Bidco Limited and Stone Point Credit Adviser LLC.+
(c)(i)   Opinion of Goldman Sachs & Co. LLC, dated July 29, 2024 (included as Annex L to the Proxy Statement and incorporated herein by reference).
(c)(ii)   Discussion Materials of Goldman Sachs & Co. LLC, dated March 26, 2024.+
(c)(iii)   Discussion Materials of Goldman Sachs & Co. LLC, dated April 4, 2024.*+
(c)(iv)   Discussion Materials of Goldman Sachs & Co. LLC, dated April 8, 2024.+
(c)(v)   Discussion Materials of Goldman Sachs & Co. LLC, dated April 10, 2024.+
(c)(vi)   Discussion Materials of Goldman Sachs & Co. LLC, dated July 28, 2024.*+
(d)(i)   Agreement and Plan of Merger dated as of July 29, 2024, by and among Elk Bidco Limited, Elk Merger Sub Limited, Enstar Group Limited, Deer Ltd. and Deer Merger Sub Ltd. (included as Annex A to the Proxy Statement and incorporated herein by reference).
(d)(ii)   Form of First Statutory Merger Agreement to be entered into by and among Deer Ltd., Deer Merger Sub Ltd. and Enstar Group Limited (included as Annex B to the Proxy Statement and incorporated herein by reference).
(d)(iii)   Form of Second Statutory Merger Agreement to be entered into by and among Deer Ltd. and Enstar Group Limited (included as Annex C to the Proxy Statement and incorporated herein by reference).

 

7

 

 

(d)(iv)   Form of Third Statutory Merger Agreement to be entered into by and among Elk Bidco Limited, Elk Merger Sub Limited, and Enstar Group Limited (included as Annex D to the Proxy Statement and incorporated herein by reference).
(d)(v)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and Dominic Silvester (included as Annex E to the Proxy Statement and incorporated herein by reference).
(d)(vi)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and David Walsh (included as Annex K to the Proxy Statement and incorporated herein by reference).
(d)(vii)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and Frazer Holdings (included as Annex H to the Proxy Statement and incorporated herein by reference).
(d)(viii)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and Hyman 2018 Family Trust (included as Annex I to the Proxy Statement and incorporated herein by reference).
(d)(ix)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and J. Christopher Flowers (included as Annex G to the Proxy Statement and incorporated herein by reference).
(d)(x)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and John J. Oros 1998 Family Trust (included as Annex J to the Proxy Statement and incorporated herein by reference).
(d)(xi)   Rollover and Support Agreement dated as of July 29, 2024, by and among Elk Topco, LLC, J.C. Flowers & Co. LLC, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC and Steven D. Arnold (included as Annex F to the Proxy Statement and incorporated herein by reference).
(d)(xii)   Shareholder Rights Agreement, dated as of November 8, 2023, by and among Enstar Group Limited, Elk Evergreen Investments, LLC and Elk Cypress Investments, LLC (incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K filed on November 13, 2023).
(d)(xiii)   Registration Rights Agreement, dated as of November 8, 2023, by and among Enstar Group Limited, Elk Evergreen Investments, LLC and Elk Cypress Investments, LLC (incorporated by reference to Exhibit 10.4 to the Company’s Form 8-K filed on November 13, 2023).
(d)(xiv)   Purchase Agreement, dated November 8, 2023, between Canada Pension Plan Investment Board, Elk Evergreen Investments, LLC and Elk Cypress Investments, LLC.+
(d)(xv)   Assignment and Assumption Agreement, dated November 8, 2023, between Canada Pension Plan Investment Board, Elk Evergreen Investments, LLC, Elk Cypress Investments, LLC, Flexpoint Asset Opportunity Fund II-A, L.P. and Flexpoint Asset Opportunity Fund II-B, L.P.+
(d)(xvi)   Purchase Agreement, dated March 23, 2023, between Enstar Group Limited and Canada Pension Plan Investment Board (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on March 28, 2023).
(d)(xvii)   Purchase Agreement, dated as of November 7, 2023, by and among Enstar Group Limited, Canada Pension Plan Investment Board, and CPPIB Epsilon Ontario Limited Partnership (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on November 13, 2023).
(d)(xviii)   Purchase Agreement, dated as of November 7, 2023, by and between Enstar Group Limited and Trident Public Equity L.P. (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed on November 13, 2023).
(d)(xix)   Form of New Rollover and Support Agreements.
(f)   Section 106 of the Bermuda Companies Act (included as Annex M to the Proxy Statement and incorporated herein by reference).

 

8

 

 

107   Filing Fee Table#

 

 

*Certain portions of this exhibit have been redacted and separately filed with the SEC pursuant to a request for confidential treatment.
+Previously filed with the Transaction Statement on the Schedule 13E-3 filed with the SEC on September 4, 2024.
#Previously filed with the Transaction Statement on the Schedule 13E-3 filed with the SEC on October 11, 2024.

 

9

 

 

SIGNATURES

 

After due inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated as of July 2, 2025

 

ENSTAR GROUP LIMITED
  
By:/s/ Audrey B. Taranto
  Name: Audrey B. Taranto
Title: General Counsel

 

ELK EVERGREEN INVESTMENTS, LLC
  
By:/s/ Joshua Peck
  Name: Joshua Peck
Title: Vice President

 

ELK CYPRESS INVESTMENTS, LLC
  
By:/s/ Joshua Peck
  Name: Joshua Peck
Title: Vice President

 

TSSP SUB-FUND HOLDCO, LLC
  
By:/s/ Joshua Peck
  Name: Joshua Peck
Title: Vice President

 

[Signature Page to Schedule 13E-3] 

 

 

 

 

ELK BIDCO LIMITED
  
By:/s/ A. Michael Muscolino
  Name: A. Michael Muscolino
Title: Authorized Signatory

 

DOMINIC F. SILVESTER
  
/s/ Dominic F. Silvester
  Name: Dominic F. Silvester

 

[Signature Page to Schedule 13E-3]

 

 

 

FAQ

What insider transaction did Jamie L. Reynoso report for CLOV?

217,523 RSUs vested and 85,596 shares were withheld for taxes on 30 June 2025.

How many Clover Health shares does Reynoso own after the Form 4 filing?

She now directly owns 3,328,328 Class A shares.

Were any open-market purchases or sales involved?

No. The acquisition came from RSU vesting; the share sale was automatic tax withholding, not discretionary trading.

At what price were shares sold to cover taxes?

Shares were sold at $2.79 per share.

Does the filing indicate use of a Rule 10b5-1 plan?

No Rule 10b5-1 box is marked; the sale was automatic for tax withholding.
Enstar Group Limited

NASDAQ:ESGR

ESGR Rankings

ESGR Latest News

ESGR Latest SEC Filings

ESGR Stock Data

5.02B
11.78M
10.79%
84.93%
1.11%
Insurance - Diversified
Fire, Marine & Casualty Insurance
Link
Bermuda
HAMILTON